Related Experiment Video
Updated: Sep 11, 2025
Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
Published on: February 22, 2019
Innovative adjuvant strategies for next-generation pertussis vaccines
Ge Yu1,2,3, Wenqi Yang1,2,3, Yubin Ma1,2,3
1State Key Laboratory of Fine Chemicals, Dalian University of Technology, Dalian, China.
Insights
New pertussis vaccines need better adjuvants to improve effectiveness against Bordetella pertussis infection and transmission. Understanding novel adjuvants is key for developing next-generation vaccines with enhanced cellular and mucosal immunity.
Area of Science:
- Immunology
- Vaccinology
- Microbiology
Background:
- Acellular pertussis (aP) vaccines replaced whole-cell pertussis (wP) vaccines due to safety.
- aP vaccines show reduced efficacy in preventing Bordetella pertussis infection and transmission.
- Current aP vaccines lack robust cellular and mucosal immunity induction.
Purpose of the Study:
- To review current pertussis vaccines, focusing on antigens and adjuvants.
- To discuss the mechanisms of novel adjuvants for pertussis vaccines.
- To identify knowledge gaps in adjuvant application for improved pertussis vaccine design.
Main Methods:
- Literature review of approved pertussis vaccines.
- Analysis of antigen and adjuvant types in current vaccines.
- Exploration of novel adjuvant mechanisms and their potential roles.
Main Results:
- Summary of existing pertussis vaccine components.
- Discussion on the limitations of current aP vaccine-induced immunity.
- Identification of novel adjuvants as a promising strategy for next-generation vaccines.
Conclusions:
- Novel adjuvants are crucial for enhancing cellular and mucosal immunity in pertussis vaccines.
- Further research into adjuvant mechanisms is needed for improved vaccine design.
- Developing next-generation pertussis vaccines requires a deeper understanding of adjuvant systems.
Abstract:
The acellular pertussis (aP) vaccine has increasingly replaced the whole-cell pertussis (wP) vaccine due to its superior safety profile. However, the aP vaccine is less effective at preventing infection and transmission of Bordetella pertussis, highlighting the need for more effective aP vaccines. Current aP vaccines do not elicit the robust cellular immunity necessary to eliminate intracellular bacteria and do not induce sufficient mucosal immunity to prevent bacterial colonization in the upper respiratory tract. Incorporating novel adjuvants represents a promising avenue for the future development of pertussis vaccines. Nevertheless, there remains a significant gap in understanding the application of novel adjuvants. In this article, we summarize the currently approved pertussis vaccines, focusing on the types of antigens and adjuvants used, and discuss the mechanisms of novel adjuvants. This provides valuable insights into the roles of adjuvants in pertussis vaccines, laying a foundation for designing next-generation pertussis vaccines with improved adjuvant systems.
More Related Videos
13:36Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
Published on: May 6, 2015
07:32Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus MRSA Infection
Published on: September 1, 2023
Related Concept Videos
01:51Vaccinations
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:29Microorganisms in Medicine and Therapeutics